Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 24346431)


Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.

Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, Dellinger MT, Castrillon DH, Brekken RA.

Cancer Res. 2014 Feb 15;74(4):1032-44. doi: 10.1158/0008-5472.CAN-13-2800. Epub 2013 Dec 17.


Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D.

Clin Cancer Res. 2011 Sep 1;17(17):5822-32. doi: 10.1158/1078-0432.CCR-11-1185. Epub 2011 Jul 7.


Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.

Bausch D, Pausch T, Krauss T, Hopt UT, Fernandez-del-Castillo C, Warshaw AL, Thayer SP, Keck T.

Angiogenesis. 2011 Sep;14(3):235-43. doi: 10.1007/s10456-011-9207-3. Epub 2011 Mar 26.


A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.

Sempere LF, Gunn JR, Korc M.

Cancer Biol Ther. 2011 Aug 1;12(3):198-207. Epub 2011 Aug 1.


Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.

Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA.

J Gastrointest Surg. 2008 Jan;12(1):57-66. Epub 2007 Nov 17.


Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.

Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, Aftab DT, McDonald DM.

Cancer Discov. 2012 Mar;2(3):270-87. doi: 10.1158/2159-8290.CD-11-0240. Epub 2012 Feb 24.


Thiol-ene hydrogels as desmoplasia-mimetic matrices for modeling pancreatic cancer cell growth, invasion, and drug resistance.

Ki CS, Lin TY, Korc M, Lin CC.

Biomaterials. 2014 Dec;35(36):9668-77. doi: 10.1016/j.biomaterials.2014.08.014. Epub 2014 Aug 28.


PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.

Ostapoff KT, Awasthi N, Cenik BK, Hinz S, Dredge K, Schwarz RE, Brekken RA.

Mol Cancer Ther. 2013 Jul;12(7):1190-201. doi: 10.1158/1535-7163.MCT-12-1123. Epub 2013 May 21.


The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.

Oncotarget. 2013 Oct;4(10):1632-46.


Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.

Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, Carano RA, Foreman O, Eastham-Anderson J, Jubb AM, Ferrara N, Johnson L.

J Pathol. 2012 Aug;227(4):417-30. doi: 10.1002/path.4053. Epub 2012 Jun 28.


MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.

Krantz SB, Shields MA, Dangi-Garimella S, Cheon EC, Barron MR, Hwang RF, Rao MS, Grippo PJ, Bentrem DJ, Munshi HG.

Mol Cancer Res. 2011 Oct;9(10):1294-304. doi: 10.1158/1541-7786.MCR-11-0023. Epub 2011 Aug 19.


A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M.

Mol Cancer Ther. 2010 Sep;9(9):2582-92. doi: 10.1158/1535-7163.MCT-10-0370. Epub 2010 Jul 26.


Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.

Lucio-Eterovic AK, Piao Y, de Groot JF.

Clin Cancer Res. 2009 Jul 15;15(14):4589-99. doi: 10.1158/1078-0432.CCR-09-0575. Epub 2009 Jun 30.


N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer.

Su Y, Li J, Witkiewicz AK, Brennan D, Neill T, Talarico J, Radice GL.

Oncogene. 2012 Oct 11;31(41):4484-9. doi: 10.1038/onc.2011.574. Epub 2011 Dec 12.


Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.

Cancer Lett. 2013 Jul 10;335(1):41-51. doi: 10.1016/j.canlet.2013.01.054. Epub 2013 Feb 10.


Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer.

Su HT, Weng CC, Hsiao PJ, Chen LH, Kuo TL, Chen YW, Kuo KK, Cheng KH.

Mol Cancer Res. 2013 Jul;11(7):768-79. doi: 10.1158/1541-7786.MCR-12-0511. Epub 2013 Apr 3.


MUC1 regulates PDGFA expression during pancreatic cancer progression.

Sahraei M, Roy LD, Curry JM, Teresa TL, Nath S, Besmer D, Kidiyoor A, Dalia R, Gendler SJ, Mukherjee P.

Oncogene. 2012 Nov 22;31(47):4935-45. doi: 10.1038/onc.2011.651. Epub 2012 Jan 23.


Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.

Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B, Rosewicz S.

Int J Oncol. 2005 Sep;27(3):669-79.


Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.

Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ, Munshi HG.

Cancer Res. 2011 Feb 1;71(3):1019-28. doi: 10.1158/0008-5472.CAN-10-1855. Epub 2010 Dec 8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk